One year experience on EU Medical Devices Regulation (MDR) 2017/745 for single integral drug-device combination products

AdobeStock_278890190

Source: Adobe Stock

 Since 26 May 2021, Article 117 of the MDR asks for a notified body opinion (NBOp) to be included in the marketing authorisation applications (MAAs) for medicinal products that are a single integral drug-device combination…

 

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

Members login

Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.

Login

REGISTER FOR FREE

Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

  • Create your own library to save your favourite content.
  • Sign up for Regulatory Rapporteur email newsletters.
Create a free account

JOIN TOPRA

TOPRA membership

Become a TOPRA member and join our global community of regulatory affairs professionals.

  • Great savings on our events and training.
  • Be part of our dynamic international community.
  • Contribute to the profession.
  • Grow your skills and knowledge.
  • Take your career to the next level.
Become a member